(S)-6-CHLORO-N2-ETHYL-N4-(1-PHENYLETHYL)-1,3,5-TRIAZINE-2,4-DIAMINE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QDWNIMWOSOMTIX-VIFPVBQESA-N
Smiles	CCNc1nc(Cl)nc(N[C@@H](C)c2ccccc2)n1
InChI	InChI=1S/C13H16ClN5/c1-3-15-12-17-11(14)18-13(19-12)16-9(2)10-7-5-4-6-8-10/h4-9H,3H2,1-2H3,(H2,15,16,17,18,19)/t9-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H16ClN5
Molecular Weight	277.75
AlogP	3.77
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	5.0
Polar Surface Area	62.73
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	19.0

Assay Description	Organism	Bioactivity
Phytotoxicity in Echinochloa crus-galli var. formosensis (barnyard millet) assessed as inhibition of photosystem II	Echinochloa crus-galli var. formosensis	17.38 nM
Herbicidal activity against Echinochloa oryzicola seedlings assessed as appearance of leaf burn symptom after 3 weeks by paddy pot test under green house conditions	Echinochloa oryzicola	None
Herbicidal activity against Echinochloa oryzicola seedlings measured per 10 acres after 3 weeks by paddy pot test under green house conditions	Echinochloa oryzicola	30.0 g
Phytotoxicity in germinated seedlings of Echinochloa crus-galli var. formosensis (barnyard millet) assessed as root growth inhibition after 3 to 4 days	Echinochloa crus-galli var. formosensis	30902.95 nM
Phytotoxicity in germinated seedlings of Oryza sativa (rice) assessed as root growth inhibition at 30 uM after 3 to 4 days	Oryza sativa	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2271668
PubChem	184138

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).